Skip to main content
editorial
. 2019 Jan 22;7(1):1562861. doi: 10.1080/20016689.2018.1562861

Figure 1.

Figure 1.

Current and potential future use of endpoints in health technology assessment of oncology drugs.

HRQoL, health-related quality of life; HTA, health technology assessment; MCID, minimal clinically important difference; OS, overall survival; PFS, progression-free survival.